Trastuzumab rezetecan: all 92 studies that test it
Page 1 of 1. Open to participants first (79), then studies with results posted, then the rest; newest registration first within each.
- Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder CancerNot yet recruitingNCT07865611Phase 2
- SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete ResponseNot yet recruitingNCT07856303Phase 2
- Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingNCT07843303Phase 2
- Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung CancerNot yet recruitingNCT07836543Phase 2
- Trastuzumab Combined With Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Receptor 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy FailureNot yet recruitingNCT07817654Phase 2
- Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast CancerRecruitingNCT07817082Phase 2
- Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07802288Phase 2
- A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2Not yet recruitingNCT07796763Phase 2
- SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast CancerNot yet recruitingNCT07787338Phase 2
- A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLCNot yet recruitingNCT07778745Phase 2
- Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian CancerNot yet recruitingNCT07776171Phase 2
- Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNot yet recruitingNCT07766772Phase 2
- An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBCNot yet recruitingNCT07760844Phase 3
- Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUCRecruitingNCT07741448Phase 2
- Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract CancerRecruitingNCT07704177Phase 2
- First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) AlterationsNot yet recruitingNCT07699952Phase 2
- A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal CancerRecruitingNCT07676162Phase 3
- Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract CancerRecruitingNCT07670273Phase 2
- Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast CancerRecruitingNCT07647263Phase 2
- Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial CarcinomaNot yet recruitingNCT07639983Phase 2
- Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid TumorNot yet recruitingNCT07631884Phase 2
- Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast CancerNot yet recruitingNCT07630103Phase 2
- Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene AbnormalitiesNot yet recruitingNCT07630077Phase 2
- Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast CancerNot yet recruitingNCT07618923Phase 2
- Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHPNot yet recruitingNCT07589699Phase 4
- Exploratory Study of SHR-A1811 Via Different Administration Routes in PatientsNot yet recruitingNCT07560475Phase 2
- Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.Not yet recruitingNCT07528898Phase 2
- Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted TherapyRecruitingNCT07528716Phase 3
- A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast CancerRecruitingNCT07497386Phase 2
- SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLCNot yet recruitingNCT07489703Phase 2
- Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver MetastasesNot yet recruitingNCT07466927Phase 2
- SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized StudyNot yet recruitingNCT07417241Phase 2
- Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast CancerNot yet recruitingNCT07416253Phase 2
- Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 SubtypeNot yet recruitingNCT07382687Phase 3
- Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLCNot yet recruitingNCT07377916Not applicable
- MA-CRC-II-016 SHR-1811Not yet recruitingNCT07355764Phase 2
- Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast CancerRecruitingNCT07340398Phase 2
- Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast CancerNot yet recruitingNCT07317778Phase 2
- Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard TherapiesRecruitingNCT07309770Phase 2
- SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II StudyNot yet recruitingNCT07307287Phase 2
- Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast CancerNot yet recruitingNCT07305246Phase 2
- A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung CancerNot yet recruitingNCT07281209Phase 2
- A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid TumorRecruitingNCT07275242Phase 1
- The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral CrisisRecruitingNCT07203729Phase 2
- Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyNot yet recruitingNCT07179939Phase 2
- SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast CancerNot yet recruitingNCT07132242Phase 2
- SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant ResponseNot yet recruitingNCT07129187Phase 2
- A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast CancerRecruitingNCT07111832Phase 3
- A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ CancerRecruitingNCT07110571Phase 2
- A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical CancerRecruitingNCT07051486Phase 2
- Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCNot yet recruitingNCT07047755Phase 2
- SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 ExpressionNot yet recruitingNCT07047443Phase 2
- SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian CancerNot yet recruitingNCT06990516Phase 1/2
- SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian CancerNot yet recruitingNCT06990503Phase 3
- A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain MetastasesNot yet recruitingNCT06975462Phase 2
- SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCRecruitingNCT06927180Phase 2
- Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular SubtypingNot yet recruitingNCT06881017Phase 2
- A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian CancerRecruitingNCT06840002Phase 1/2
- A Study of SHR-A1811 in Subjects With Ovarian CancerRecruitingNCT06828354Phase 3
- A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer PatientsNot yet recruitingNCT06788197Phase 1/2
- A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract CancerRecruitingNCT06778031Phase 2
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingNCT06649331Phase 2
- Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer PatientsNot yet recruitingNCT06592625Phase 2
- A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 MutationsRecruitingNCT06430437Phase 3
- SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast CancerRecruitingNCT06411457Phase 2
- SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain MetastasesNot yet recruitingNCT06361979Phase 2
- SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast CancerRecruitingNCT06340230Phase 2
- SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing RegimenRecruitingNCT06123494Phase 3
- A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast CancerRecruitingNCT05911958Phase 2
- A Study of SHR-A1811 in Subjects With Gynaecologic OncologyRecruitingNCT05896020Phase 2
- A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.RecruitingNCT05845138Phase 1/2
- A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.Not yet recruitingNCT05792410Phase 1/2
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingNCT05749588Phase 2
- Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric CancerRecruitingNCT05671822Phase 2
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
- A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung CancerRecruitingNCT05482568Phase 1/2
- A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing CancersEnrolling by invitationNCT05349409Phase 2
- Reverse Triple Negative Immune Resistant Breast CancerRecruitingNCT05076682Phase 2
- A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast CancerActive, not recruitingNCT07196774Phase 3
- Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast CancerCompletedNCT06710990Phase 1
- Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract CancerActive, not recruitingNCT06413745Phase 2
- Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and IrinotecanActive, not recruitingNCT06199973Phase 3
- A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant TherapyActive, not recruitingNCT06126640Phase 3
- A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast CancerActive, not recruitingNCT06057610Phase 3
- A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular TypingActive, not recruitingNCT05924256Phase 2
- Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）Active, not recruitingNCT05824325Phase 1/2
- SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical TrialActive, not recruitingNCT05814354Phase 3
- A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxaneActive, not recruitingNCT05424835Phase 3
- A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung CancerActive, not recruitingNCT04818333Phase 1/2
- A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing TumorsCompletedNCT04513223Phase 1
- A Study of SHR-A1811 in Subjects With Advanced Malignant Solid TumorsCompletedNCT04446260Phase 1